Futures surge 2% higher on positive Remdesivir news from Gilead -
S&P futures skyrocket after Gilead (GILD) issues statement on data emerging from NIAID study of investigational antiviral remdesivir for the treatment of COVID-19; company understands that the trial has met its primary endpoint (290.75 +4.96)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.